DRMA 1.25 Dermata Therapeutics, Inc.
Range: | 1.29-14.625 | Vol Avg: | 2555371 | Last Div: | 0 | Changes: | 0.01 |
Beta: | 0.78 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Fri Aug 13 2021 | Empoloyees: | 8 |
CUSIP: | 249845108 | CIK: | 0001853816 | ISIN: | US2498453065 | Country: | US |
CEO: | Mr. Gerald T. Proehl | Website: | https://www.dermatarx.com |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.